Overview Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL Status: Not yet recruiting Trial end date: 2024-01-01 Target enrollment: Participant gender: Summary The purpose of this study is to assess the efficacy and safety of APG-2575 single agent in patients with relapsed/refractory CLL/SLL. Phase: Phase 2 Details Lead Sponsor: Ascentage Pharma Group Inc.